Oxbow Advisors’s ResMed RMD Stock Holding History

Oxbow Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.28M	Buy	27,963 +392	+1%	+$97.7K	0.53%	51
2025 Q4	$6.64M	Buy	27,571 +50	+0.2%	+$12.8K	0.58%	49
2025 Q3	$7.53M	Buy	27,521 +235	+0.9%	+$64.2K	0.7%	31
2025 Q2	$7.04M	Buy	27,286 +14,701	+117%	+$3.51M	0.77%	28
2025 Q1	$2.82M	Buy	12,585 +245	+2%	+$57.2K	0.3%	72
2024 Q4	$2.82M	Buy	12,340 +34	+0.3%	+$8.19K	0.33%	67
2024 Q3	$3M	Buy	12,306 +364	+3%	+$81.3K	0.3%	65
2024 Q2	$2.29M	Buy	+11,942	New	+$2.42M	0.27%	69

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oxbow Advisors's RMD Position: Q1 2026 in Review

Oxbow Advisors increased its ResMed (RMD) stake by 1.4% in Q1 2026, buying an estimated $97.7K and bringing the position to 27,963 shares worth $6.28M. The position accounts for 0.53% of the portfolio, ranked #51.

Oxbow Advisors first reported a position in RMD in Q2 2024 and has held it in 8 quarters since. The position peaked at $7.53M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Oxbow Advisors held 27,963 shares of ResMed worth $6.28M as of Q1 2026.
Oxbow Advisors bought 392 ResMed shares in Q1 2026, an estimated $97.7K.
ResMed made up 0.53% of Oxbow Advisors's portfolio in Q1 2026, its #51 holding.
Oxbow Advisors first reported a position in ResMed in Q2 2024 and has held it in 8 quarters since.
Oxbow Advisors's ResMed position peaked at $7.53M in Q3 2025.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Oxbow Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.